« Back to results
  • Added 16 Apr 2013
  • Expires

PATH Malaria Vaccine Initiative (MVI)

Details

The PATH Malaria Vaccine Initiative (MVI) is a global program of the international nonprofit organization PATH. MVI was established in 1999 through a grant from the Bill & Melinda Gates Foundation. Our mission isto accelerate the development of malaria vaccines and catalyze timely access in endemic countries. We identify potentially promising malaria vaccine approaches and systematically move them through the development process. At the same time, we work to ensure that a successful malaria vaccine will be widely available and accessible in the countries that need it most. MVI works with partners in private industry, government, and academia to develop safe and effective vaccines for malaria. We are pursuing new business initiatives and vaccine development collaborations to further strengthen our malaria vaccine pipeline. Partnering with us may include the following: 1. Developing combinations of antigens. We believe that combining pre-erythrocytic and blood-stage antigens offers a high probability of success. 2. Identifying new immunopotentiators and delivery platforms. New and safe immunopotentiators are needed to enhance the magnitude and duration of immune responses to recombinant malaria vaccines. There is also a need for new vaccine platforms that utilize improved methods of vaccine delivery to the desired targets inside the human body. 3. Developing evaluation technologies. We are eager to direct resources toward developing new and refined assays to efficiently and consistently assess the potential effectiveness of vaccine candidates. We are eager to direct resources toward developing new and refined assays to efficiently and consistently assess the potential effectiveness of vaccine candidates.

Inclusion Criteria

Populations with malaria (further inclusion criteria will be available for each individual study).

Contact

PATH-MVI would be really interested to hear from any sites who would be interested in working with us on future studies. Please contact us with your site profile information if you are interested.

Respond to this study

Please Login to respond to a study.